Using a Smart Inhaler to Support Asthma Management in Adolescents With Intellectual and Developmental Disabilities

Inclusion Criteria: Participants must meet all of the inclusion criteria to participate in this study:

• Adolescents ages 10-17 years

• Diagnosis of mild-to-moderate intellectual disability: ICD-10: F70-F71 and/ordiagnosis of developmental disability, including autism: ICD-10: F80-89

• Diagnosis of moderate-to-severe asthma or moderate or severe unspecified asthma:ICD-10: J45.40-J45.909

• Parent/legal guardian is willing to answer questions about their child.

• Parent/legal guardian and adolescent must have the ability to understand studyprocedures and to comply with them for the entire length of the study

• English or Spanish-speaking participants

• Not involved in other studies using digital inhalers

• Males and females of reproductive capability will be enrolled: contraception is notnecessary or required.

• Participants must use any of the following MDIs (as indicated by the 510(k):Ventolin HFA, ProAir HFA, Advair HFA, Flovent HFA, Xopenex HFA, Symbicort HFA,Atrovent HFA, Proventil HFA, Alvesco HFA, Dulera HFA, and Asmanex HFA.

Exclusion Criteria: All candidates meeting any of the exclusion criteria at baseline will be excluded from study participation:

• Health status or any clinical conditions: Limited life expectancy, co-existingdisease or other characteristics that precludes appropriate diagnosis, treatment, orfollow-up in the trial.

• Inability or unwillingness of individual or legal guardian/representative to givewritten informed consent.